Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - l-amlodipina, valsartan - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. dafiro huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. exforge huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - pressjoni għolja - antagonisti ta 'angiotensin ii, sempliċi - hypertensiontreatment ta'l-ipertensjoni essenzjali fl-adulti. kardjovaskulari preventionreduction tal-morbidità kardjovaskulari f'pazjenti bi: - manifest aterotrombotiċi mard kardjovaskulari (passat ta ' mard koronarju tal-qalb, puplesija, jew mard arterjali periferali) jew;dijabete tat-tip 2 mellitus dokumentata-mira-ħsara fl-organi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - patiromer sorbitex calcium - iperkalemija - - mediċini għal-kura tal-iperkalimja u ' l-iperphosphatemija - veltassa huwa indikat għall-kura ta 'iperkalimja fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rifjut ta 'graft - immunosoppressanti - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novo nordisk a/s - liraglutide - obesity; overweight - drogi użati fid-dijabete - saxenda huwa indikat bħala żieda mad-mnaqqsa dieta ta 'kaloriji u żieda fl-attività fiżika għall-ġestjoni tal-piż f'pazjenti adulti b'inizjali indiċi tal-massa tal-Ġisem (bmi) tal• ≥ 30 kg/m2 (obeżi), jew• ≥ 27 kg/m2 sa < 30 kg/m2 (piż żejjed) fil-preżenza ta' mill-inqas wieħed mill-piż relatata mal-ko-morbidità bħal dysglycaemia (pre-dijabete jew dijabete mellitus tip 2), pressjoni għolja, dislipidemija jew apnea waqt l-irqad. it-trattament b'saxenda għandu jitwaqqaf wara 12-il ġimgħa fuq l-3. 0 mg/kuljum-doża jekk il-pazjenti ma jkunux tilfu tal-inqas 5% tal-inizjali tagħhom piż tal-ġisem.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novo nordisk a/s - l-insulina degludec, liraglutide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - xultophy huwa indikat għall-kura ta ' l-adulti ma tip-2 diabetes mellitus biex jitjieb il-kontroll ta ' glycaemic flimkien ma ' l-orali li jitbaxxew il-glukosju prodotti mediċinali meta dawn waħedhom jew kombinati ma ' tal-glp-1 riċevitur agonist jew ta ' insulina bażali ma jipprovdux kontroll adegwat ta ' glycaemic.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novo nordisk a/s - liraglutide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - victoza huwa indikat għat-trattament ta ' adulti, l-adoloxxenti u t-tfal bejn l-10 snin u l-fuq li mhumiex ikkontrollati biżżejjed bil-dijabete tat-tip 2 mellitus bħala żieda mad-dieta u l-exerciseas monoterapija b'metformin meta jitqies mhux xieraq minħabba l-intolleranza jew contraindicationsin minbarra l-oħra prodotti mediċinali għall-kura tad-dijabete. għall-riżultati tal-istudju fir-rigward tal-kombinazzjonijiet, l-effetti fuq il-kontroll gliċemiku u episodji kardjovaskulari, u l-popolazzjonijiet studjati.